OncoMatch/Clinical Trials/NCT05856643
Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma
Is NCT05856643 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies SZ011 CAR-NK for ovarian epithelial carcinoma.
Treatment: SZ011 CAR-NK — This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of ovarian epithelial carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: MSLN positive expression (positive)
Demographics
Prior therapy
Must have received: first-line treatment
Ovarian cancer patients who have failed or relapsed after first-line treatment
Lab requirements
Blood counts
absolute neutrophil count 1.5109/L; platelets count 50109/L; hemoglobin 80g/L; serum albumin 2.5g/dL
Kidney function
serum creatinine 1.5 times ULN
Liver function
bilirubin 1.5 times ULN; ALT and AST 3 times ULN
absolute neutrophil count 1.5109/L; platelets count 50109/L; hemoglobin 80g/L; serum albumin 2.5g/dL; bilirubin 1.5 times ULN; ALT and AST 3 times ULN; serum creatinine 1.5 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05856643 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received first-line treatment.
Does this trial require MSLN?
Yes, MSLN positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages